Insider Trading June 5, 2026 05:21 PM

CRA International CEO Paul Maleh Executes $1M+ Stock Sale Under Pre-Arranged Plan

Executive divestment coincides with Q1 revenue growth but EPS shortfall; shares trade below analyst valuations despite YTD decline.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
CRAI

Paul A Maleh, President and Chief Executive Officer of CRA International, Inc. (NASDAQ:CRAI), executed a series of stock sales totaling 7,500 shares on June 3, 2026, with a combined transaction value of $1,026,244. The sales were carried out under a Rule 10b5-1 trading plan established on November 19, 2025. The transactions occurred across multiple price tiers, with shares sold between $134.04 and $142.4675. Following the divestment, Maleh retains direct ownership of 111,050 shares. The sale takes place as CRAI stock trades at $145.71, reflecting a 28% year-to-date decline. Despite this price movement, analytical assessments suggest the stock may be undervalued, with consensus price targets ranging from $245 to $260. The company maintains a market capitalization of $943 million and trades at a price-to-earnings ratio of 20.21. In recent financial reporting, CRA International disclosed Q1 2026 results featuring record revenue of $201 million, a 10.5% year-over-year increase. However, earnings per share fell short of projections at $1.99 versus the expected $2.06. This divergence between top-line growth and bottom-line performance highlights operational complexities in maintaining profitability margins. Investors and analysts are closely monitoring how the firm addresses these earnings pressures in subsequent quarters. The financial data underscores the importance of balancing revenue expansion with earnings consistency in the consulting and analytics sector.

CRA International CEO Paul Maleh Executes $1M+ Stock Sale Under Pre-Arranged Plan
CRAI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Paul A Maleh sold 7,500 shares of CRAI stock on June 3, 2026, under a pre-arranged Rule 10b5-1 trading plan.
  • CRA International reported Q1 2026 revenue of $201 million, a 10.5% increase, but EPS of $1.99 missed the $2.06 projection.
  • The stock trades at $145.71, down 28% year-to-date, with analysts setting price targets between $245 and $260.

Paul A Maleh, President and Chief Executive Officer of CRA International, Inc. (NASDAQ:CRAI), executed a series of stock sales totaling 7,500 shares on June 3, 2026, with a combined transaction value of $1,026,244. The sales were carried out under a Rule 10b5-1 trading plan established on November 19, 2025.

The transactions occurred across multiple price tiers, with shares sold between $134.04 and $142.4675. Following the divestment, Maleh retains direct ownership of 111,050 shares. The sale takes place as CRAI stock trades at $145.71, reflecting a 28% year-to-date decline. Despite this price movement, analytical assessments suggest the stock may be undervalued, with consensus price targets ranging from $245 to $260. The company maintains a market capitalization of $943 million and trades at a price-to-earnings ratio of 20.21.

In recent financial reporting, CRA International disclosed Q1 2026 results featuring record revenue of $201 million, a 10.5% year-over-year increase. However, earnings per share fell short of projections at $1.99 versus the expected $2.06. This divergence between top-line growth and bottom-line performance highlights operational complexities in maintaining profitability margins. Investors and analysts are closely monitoring how the firm addresses these earnings pressures in subsequent quarters. The financial data underscores the importance of balancing revenue expansion with earnings consistency in the consulting and analytics sector.

Risks

  • The discrepancy between revenue growth and earnings performance may signal margin pressure or cost challenges in the consulting sector.
  • The 28% year-to-date stock decline could indicate broader market skepticism or valuation adjustments for professional services firms.
  • Investors will monitor future quarters to see if the company can reconcile top-line expansion with improved bottom-line results.

More from Insider Trading

Rocket Lab Director Slusky Offloads $4.94M in Equity Amid Sector Valuation Debate Jun 5, 2026 Xeris Biopharma Director Marla Persky Executes Strategic Share Transactions Amidst Financial Momentum Jun 5, 2026 Getty Images Executive Offloads Shares Amidst Merger Uncertainty and Earnings Miss Jun 5, 2026 Datadog Director Dev Ittycheria Offloads $34.3 Million in Shares Amid Strong Stock Performance Jun 5, 2026 Xeris Biopharma Director John Johnson Executes Share Transactions Amidst Strong Quarterly Performance Jun 5, 2026